Kiniksa Pharmaceuticals International (KNSA) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

KNSA Kiniksa Pharmaceuticals International

Watchlist

20.310
+0.370+1.86%

Close Jan 3 16:00 ET

18.000
-2.310-11.37%

Pre 05:07 ET

1.47BMarket Cap-169.25P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Climbs 3.6% This Week, Taking Three-year Gains to 83%
Simply Wall St45minutes ago
Insider Sale: CHIEF ACCOUNTING OFFICER of $KNSA (KNSA) Sells 9 Shares
Quiver QuantitativeDec 2, 2024 16:46 ET
Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference
Kiniksa PharmaceuticalsNov 26, 2024 00:00 ET
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $357,680, According to a Recent SEC Filing
MT NewswiresNov 20, 2024 16:43 ET
US Manufacturing Index Rises To 43, Highest Since 2020
Business TodayNov 16, 2024 02:13 ET
Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference
GlobeNewswireNov 12, 2024 16:01 ET

Comments

TrendTrader

Jul 23, 2024 11:19

Looking for 30

$Kiniksa Pharmaceuticals International (KNSA.US)$

Moomoo AI

Feb 28, 2024 07:16

The share price rise is a fair reaction to the company's revenue growth. More gains could follow if the trend continues. Yet, consider the company's profitability and cash flow before investing.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Delivers Shareholders Respectable 66% Return Over 1 Year, Surging 4.7% in the Last Week Alone

Moomoo AI

Jan 23, 2024 06:38

Kiniksa Pharmaceuticals' low P/S ratio may be due to its forecast growth being lower than the industry. Shareholders accept this, conceding future revenue probably won't surprise positively. It's hard to see the share price rising strongly soon under these circumstances.

Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Low P/S No Reason For Excitement

Meltyy

Jan 3, 2024 06:11

Upcoming Ph 2 readouts in Q1 2024…

$Cellectar BioSciences (CLRB.US)$ Phase 2
$Regenxbio (RGNX.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals (EYPT.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Disc Medicine (IRON.US)$ Phase 2
$Atea Pharmaceuticals (AVIR.US)$ Phase 2
$Allakos (ALLK.US)$ Phase 2...

Moomoo AI

Dec 8, 2023 10:12

Kiniksa Pharmaceuticals' growing cash burn is offset by substantial cash reserves & signs of business growth. The firm can issue shares or borrow cheaply to fund further growth.

We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn

Heat List

Overall

No Data